Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

198/433 Matches for
“Screening”

“Screening” Clear all
  1. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 100

    …Hepatocellular carcinoma screening must continue in patients with liver stiffness by FibroScan…

    FibroTest HCV

  2. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 100

    …The optimal values of TyG, for screening simple steatosis and NASH were…

    NashTest SteatoTest Metabolic

  3. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 100

    …diseases and in the fibrosis screening of patients with diabetes. One challenge…

    FibroTest Alcohol HBV HCV +3

  4. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.

    Liu S et al. · PLoS One · 2011 Match 100

    …In clinical settings where testing is required, FibroTest screening is a cost…

    FibroTest HCV

  5. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 99

    …support DDA reimbursement and a screening strategy, such as the USA baby…

    ActiTest FibroTest Alcohol HBV +3

  6. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 99

    FibroTest Other

  7. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 99

    …Existing guidelines do not advocate screening for liver related complications amongst persons…

    FibroTest Metabolic

  8. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 99

    …Coinciding with new treatment options are novel methodologies for disease screening and…

    ActiTest FibroTest HCV

  9. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 98

    FibroTest Other

  10. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 98

    ActiTest AshTest FibroTest NashTest +6

  11. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 98

    FibroTest HCV

  12. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022 Match 98

    …Endoscopic screening for oesophageal varices can be avoided in patients with LSM…

    FibroTest Alcohol HBV HCV +1

  13. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 97

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  14. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 97

    FibroTest Metabolic

  15. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 97

    …We examined the efficacy of a screening strategy with a noninvasive fibrosis…

    FibroTest SteatoTest Metabolic

  16. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 97

    …A medico-economic analysis compared the screening strategies with liver biopsy. ### Results…

    FibroTest HCV

  17. Noninvasive assessment of portal hypertension in patients with cirrhosis.

    Thabut D et al. · Hepatology · 2011 Match 96

    …but are still under development. Screening tools for large populations must be…

    FibroTest Alcohol HBV HCV +3

  18. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review

    Surial B et al. · Liver Int · 2021 Match 96

    ### Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%-50…

    FibroTest HBV

  19. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 96

    …In this article, the authors evaluate current methods in NASH screening and…

    FibroTest Metabolic

  20. American Association for the Study of the Liver

    Match 96

    FibroTest HCV

  21. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.

    Thabut D et al. · Liver Int · 2006 Match 95

    …Therefore, cirrhotic patients frequently undergo screening endoscopy. As portal hypertension is related…

    FibroTest Alcohol HBV HCV

  22. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 95

    ActiTest FibroTest HBV

  23. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 95

    ### Aim To compare noninvasive methods presently used for steatosis detection and quantification…

    SteatoTest Metabolic

  24. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014 Match 95

    …larger patient numbers and performance of screening endoscopies appears justified and desirable.

    FibroTest Other

  25. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 94

    …50 countries, can facilitate the screening and management of the most frequent…

    ActiTest AshTest FibroTest NashTest +7

  26. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 94

    FibroTest HBV

  27. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 94

    FibroTest Alcohol

  28. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 94

    FibroTest Alcohol HBV HCV +1

  29. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 93

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  30. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 93

    …12 countries, can facilitate the screening and management of the most frequent…

    ActiTest FibroTest Alcohol HBV +2

  31. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 93

    …Non-invasive diagnostics of liver injury may be useful in screening to…

    ActiTest FibroTest SteatoTest Metabolic

  32. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Match 93

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  33. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014 Match 92

    …cirrhosis current guidelines recommend periodical screening for the presence of oesophageal varices…

    FibroTest HCV

  34. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 92

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  35. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Match 92

    …It is an attractive tool for large-scale screening of HCV carriers.

    FibroTest HCV

  36. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 92

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  37. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2012 Match 91

    …They can be useful in clinical practice and for large-scale screening.

    FibroTest HCV

  38. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 91

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  39. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 91

    ActiTest FibroTest NashTest-2 Metabolic

  40. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 91

    …be tailored to first tier screening of patients at risk, in order…

    FibroTest Alcohol

  41. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 90

    FibroTest SteatoTest Metabolic

  42. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 90

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  43. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 90

    ### Background Few data are available on chronic hepatitis C (CHC) in elderly…

    FibroTest HCV

  44. Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?

    Ofei SY et al. · Int J Cardiol · 2015 Match 90

    FibroTest Other

  45. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 89

    …Thus far, however, it cannot replace upper endoscopy for screening of esophageal…

    FibroTest HBV HCV

  46. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 89

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  47. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 89

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  48. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 89

    ### Background Acoustic radiation force impulse (ARFI) imaging is a new non-invasive…

    FibroTest Alcohol HBV HCV +3

  49. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 88

    …Although it lacks sensitivity, ultrasonography is an accepted tool for steatosis screening

    ActiTest FibroTest NashTest SteatoTest +1

  50. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 88

    …selection of patients for hepatocellular carcinoma surveillance and varices screening is highlighted.

    FibroTest Alcohol HBV HCV +1

  51. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 88

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  52. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.

    Bonnard P et al. · Am J Trop Med Hyg · 2010 Match 88

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…

    FibroTest HBV

  53. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 87

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  54. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 87

    …are recommended for large-scale screening studies, because imaging is less accessible…

    NashTest-2 SteatoTest-2 Metabolic

  55. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 87

    ActiTest FibroTest HCV

  56. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 87

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  57. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 86

    Although most hepatitis C virus (HCV) infections are acquired by injection drug…

    FibroTest

  58. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 86

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  59. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

    Castéra L et al. · J Hepatol · 2009 Match 86

    …compared with other available methods, but cannot replace endoscopy for OV screening.

    FibroTest HCV

  60. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 86

    …A medico-economic analysis compared the screening strategies with liver biopsy. ### Results…

    FibroTest HCV

  61. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Match 85

    …Biomarkers could be useful for screening of advanced fibrosis and NASH in…

    FibroTest NashTest SteatoTest Metabolic

  62. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 85

    …could be recommended as pre-screening that may allow physicians to narrow…

    FibroTest Alcohol HBV HCV +3

  63. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 85

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  64. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021 Match 85

    ### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…

    ActiTest FibroTest HCV

  65. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 84

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  66. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

    Myers RP et al. · AIDS · 2003 Match 84

    ### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…

    FibroTest HCV HIV

  67. Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C (Letter)

    Match 84

    FibroTest HCV

  68. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 84

    …This fact makes the screening of patients at risk of chronic liver…

    ActiTest FibroTest Alcohol HBV +3

  69. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Match 83

    FibroTest Alcohol HBV HCV +1

  70. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 83

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  71. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 83

    ActiTest AshTest FibroTest NashTest +7

  72. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 83

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  73. Combination of fibrosis tests: sequential or synchronous?

    Boursier J et al. · Hepatology · 2009 Match 82

    FibroTest HCV

  74. Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.

    · Geriatr Gerontol Int · 2015 Match 82

    FibroTest HCV

  75. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 82

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  76. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 82

    FibroTest Alcohol HBV HCV +3

  77. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

    Patel K et al. · Aliment Pharmacol Ther · 2016 Match 81

    ### Background Assessment of fibrosis progression in chronic liver disease relies upon non…

  78. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 81

    ### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…

    FibroTest

  79. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 81

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  80. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 81

    …are no clear guidelines for screening and/or monitoring individuals with UCDs…

    ActiTest FibroTest Other

  81. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 80

    …After initial screening, 1020 articles were reviewed independently by both reviewers. Eleven…

    FibroTest Alcohol

  82. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 80

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  83. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 80

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  84. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 80

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  85. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020 Match 79

    Fontan-palliated patients are at risk for the development of Fontan-associated…

    FibroTest Other

  86. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 79

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  87. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 79

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  88. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 79

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  89. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 78

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  90. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 78

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  91. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 78

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  92. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 78

    …be used as a primary screening method, allowing for a significant reduction…

    FibroTest Other

  93. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 77

    ### Context Recently, it has been shown that an allele in the adiponutrin…

    FibroTest Metabolic

  94. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 77

    ### Introduction We present two consensus definitions of advanced and late stage liver…

    FibroTest HBV HCV

  95. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 77

    …ALD could allow a large screening of the severe forms of this…

    FibroTest Alcohol

  96. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 77

    ### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…

    ActiTest FibroTest HCV

  97. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 76

    ### Background & Aims Although methotrexate (MTX) is used in the effective treatment of…

    FibroTest Other

  98. Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?

    Sebastiani G et al. · Hepatology · 2012 Match 76

    FibroTest HCV

  99. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

    Sebastiani G et al. · J Hepatol · 2006 Match 76

    …94% accuracy) using APRI as screening test, followed by Fibrotest in APRI…

    FibroTest HCV

  100. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 75

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest

  101. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 75

    ActiTest FibroTest HCV

  102. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 75

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  103. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014 Match 75

    Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…

    FibroTest HBV

  104. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 74

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  105. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 74

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  106. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

    Halfon P et al. · J Hepatol · 2007 Match 74

    ### Background/Aims We evaluated the test performance profile (TPP) of blood tests…

    FibroTest HCV

  107. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 74

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  108. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010 Match 73

    ### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…

    FibroTest HBV HCV

  109. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Match 73

    FibroTest HBV

  110. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 73

    ### Background & Aims The aim of this study was to determine the diagnostic…

    FibroTest Alcohol

  111. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 73

    FibroTest Metabolic

  112. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 72

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  113. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Match 72

    ### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…

    FibroTest HCV

  114. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 72

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  115. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010 Match 72

    ### Objectives To optimize the performance and feasibility of fibrosis blood tests and…

    FibroTest HCV

  116. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 71

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  117. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 71

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  118. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 71

    ### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…

    FibroTest Metabolic

  119. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.

    Calès P et al. · Gastroenterol Clin Biol · 2008 Match 71

    ### Objective To evaluate the rates of reliable diagnosis of cirrhosis by two…

    FibroTest HCV

  120. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.

    Boursier J et al. · Eur J Gastroenterol Hepatol · 2009 Match 70

    ### Objective Blood tests are usually designed to identify significant fibrosis. We evaluated…

    FibroTest HCV

  121. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 70

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  122. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 70

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  123. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 70

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  124. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 69

    Liver fibrosis and activity indexes were validated in patients infected by hepatitis…

    ActiTest FibroTest HCV

  125. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 69

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  126. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 69

    ### Background Liver fibrosis is a sign of advanced liver disease and is…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  127. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 69

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  128. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.

    Moussalli J et al. · Gastroenterol Res Pract · 2010 Match 68

    Barriers to management of HCV in injection drug users are related to…

    ActiTest FibroTest HCV

  129. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 68

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  130. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 68

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…

    FibroTest

  131. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 68

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  132. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 67

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  133. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 67

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  134. Guidelines for the diagnosis of uncomplicated cirrhosis.

    Fontaine H et al. · Gastroenterol Clin Biol · 2007 Match 67

    FibroTest Alcohol HBV HCV +2

  135. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 67

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  136. A reference material for traceability of aspartate aminotransferase (AST) results.

    Férard G et al. · Clin Chem Lab Med · 2005 Match 66

    Standardization of aspartate aminotransferase (AST) determination is highly desirable for inter-laboratory…

    HBV HCV

  137. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.

    Sökücü S et al. · Scand J Infect Dis · 2010 Match 66

    The aim of this study was to investigate whether the non-invasive…

    ActiTest FibroTest HBV

  138. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 66

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  139. Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

    White DL et al. · Dig Dis Sci · 2012 Match 66

    ### Aim We evaluated the association between two medications that alter bioavailable androgen…

    ActiTest FibroTest HCV

  140. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 65

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  141. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.

    Montaudié H et al. · J Eur Acad Dermatol Venereol · 2011 Match 65

    ### Background/Aim To define practical use and to specify the ideal method…

    FibroTest Other

  142. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 65

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  143. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.

    Callewaert N et al. · Nat Med · 2004 Match 65

    We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers…

    FibroTest Alcohol Other

  144. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 64

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  145. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 64

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  146. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 64

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  147. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

    Myers RP et al. · Am J Gastroenterol · 2002 Match 64

    ### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…

    FibroTest HCV

  148. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.

    Miailhes P et al. · J Viral Hepat · 2011 Match 63

    Transient elastography (TE) is a noninvasive technique to evaluate liver fibrosis. We…

    FibroTest HBV HIV

  149. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 63

    ### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…

    HCV

  150. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 63

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  151. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 63

    ### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…

    FibroTest Metabolic

  152. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.

    Köksal İ et al. · Turk J Gastroenterol · 2018 Match 62

    ### Background/Aims The hepatitis C virus (HCV) infection is important cause of…

    FibroTest HCV

  153. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 62

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  154. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

    Colletta C et al. · Hepatology · 2005 Match 62

    The course of hepatitis C virus (HCV) infection carriers with normal/near…

    FibroTest HCV

  155. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Match 62

    ### Objective Studies have shown that patients with failing Fontan circulation may develop…

    ActiTest FibroTest Other

  156. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Match 61

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  157. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 61

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  158. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 61

    ### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…

    FibroTest Alcohol HBV HCV +2

  159. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 61

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  160. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 60

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  161. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Match 60

    ### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…

    FibroTest Other

  162. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 60

    ### Background We previously reported on serum N-glycans as markers for the…

    FibroTest HBV

  163. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 60

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  164. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 59

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  165. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 59

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  166. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 59

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  167. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 59

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  168. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 58

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  169. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 58

    ### Background And Aims Hepatobiliary disorders, associated either with extraintestinal manifestations or with…

    FibroTest Other

  170. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.

    Halfon P et al. · Antivir Ther · 2009 Match 58

    ### Background Non-invasive liver fibrosis scores have been proposed as alternatives to…

    FibroTest HCV HIV

  171. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 58

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  172. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 57

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  173. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007 Match 57

    ### Background The best technique to estimate portal hypertension (PHT) is to measure…

    FibroTest Alcohol HBV HCV +2

  174. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 57

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  175. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 57

    ### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…

    FibroTest Other

  176. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.

    Calès P et al. · Liver Int · 2008 Match 56

    ### Background The reliable diagnosis rate of diagnostic tests is provided by their…

    FibroTest HCV

  177. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 56

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  178. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 56

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  179. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014 Match 56

    ### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…

    FibroTest HCV

  180. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 55

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  181. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 55

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  182. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Match 55

    ### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…

    ActiTest FibroTest HBV

  183. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

    Zarski JP et al. · Liver Int · 2010 Match 55

    ### Background The efficacy of a maintenance therapy in non-responder patients with…

    ActiTest FibroTest HCV

  184. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 54

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  185. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 54

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  186. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 54

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  187. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 54

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  188. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 53

    SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…

    ActiTest FibroTest HCV

  189. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 53

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  190. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 53

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  191. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 53

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  192. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 52

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  193. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 52

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  194. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 52

    ### Background Chronic HCV is one of the major causes of morbidity and…

    FibroTest HCV

  195. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 52

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  196. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 51

    ActiTest FibroTest HBV

  197. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

  198. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 51

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

Showing the full result list. The page is server-rendered and not paginated.